Clinical Report: Addressing Residual Risk in Atherosclerotic Cardiovascular Disease
Overview
Patients with atherosclerotic cardiovascular disease (ASCVD) continue to experience significant residual risk despite achieving lipid management goals. This report highlights the role of inflammatory markers like hs-CRP and Lp(a) in assessing this risk.
Background
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality, with many patients experiencing residual risk even after reaching recommended lipid levels. This residual risk is influenced by various factors, including inflammation and genetic predispositions.
Data Highlights
No numerical data provided in the source material.
Key Findings
Residual risk in ASCVD persists despite guideline-recommended lipid levels.
High-sensitivity C-reactive protein (hs-CRP) is recognized as a valuable inflammatory-risk marker.
Lipoprotein(a) [Lp(a)] measurement is recommended for assessing genetically influenced cardiovascular risk.
Low-dose colchicine may be considered for secondary prevention in selected ASCVD patients.
In China, routine measurement of hs-CRP and Lp(a) testing is limited, impacting risk assessment.
Immediate priorities include one-time Lp(a) assessment and context-specific evaluation of hs-CRP.
Clinical Implications
Healthcare providers should consider the role of hs-CRP and Lp(a) assessments in ASCVD patients. The use of low-dose colchicine for secondary prevention should be evaluated in appropriately selected patients.
Conclusion
Addressing residual risk in ASCVD through a multimodal approach, including inflammatory markers, is essential.
Patients with lower nonischemic resting full-cycle ratio values had more repeat revascularizations despite similar 2-year major cardiovascular event rates.
